3/26
08:20 am
pstv
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors [Yahoo! Finance]
Low
Report
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors [Yahoo! Finance]
3/26
07:30 am
pstv
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
Low
Report
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
3/19
02:52 pm
pstv
Plus Therapeutics (PSTV) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $3.00 price target on the stock.
Low
Report
Plus Therapeutics (PSTV) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $3.00 price target on the stock.
3/19
07:30 am
pstv
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
Low
Report
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
3/12
04:23 pm
pstv
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout [Yahoo! Finance]
High
Report
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout [Yahoo! Finance]
3/12
04:15 pm
pstv
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
High
Report
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
2/25
08:03 am
pstv
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ [Yahoo! Finance]
Medium
Report
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ [Yahoo! Finance]
2/25
07:30 am
pstv
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
Medium
Report
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
2/6
07:12 pm
pstv
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]
Low
Report
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]
2/3
09:00 am
pstv
Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.
Low
Report
Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.
1/23
07:09 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/22
11:40 am
pstv
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]
Low
Report
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]
1/22
10:45 am
pstv
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]
Low
Report
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]
1/22
08:06 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at D. Boral Capital from $5.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at D. Boral Capital from $5.00 to $4.00. They now have a "buy" rating on the stock.
1/22
07:45 am
pstv
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
Medium
Report
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
1/21
05:50 pm
pstv
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET [Yahoo! Finance]
Medium
Report
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET [Yahoo! Finance]
1/21
04:15 pm
pstv
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
Low
Report
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
1/14
08:00 am
pstv
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
High
Report
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
1/8
08:23 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
1/8
07:42 am
pstv
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases [Yahoo! Finance]
Medium
Report
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases [Yahoo! Finance]
1/8
07:30 am
pstv
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
Medium
Report
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases